The intrapituitary mechanisms underlying the inhibitory actions of hyperprolactinaemia on the reproductive axis remain unclear. Previous work on primary pituitary cultures revealed combined suppressive effects of prolactin (PRL) and dopamine on the gonadotrophin response to GnRH. However, whether these effects occur directly at the level of the gonadotroph and are accompanied by changes in gene expression is still unresolved. Here, aT 3 -1 and LbT2 cells were used to investigate the effects of PRL and dopamine on gonadotrophin synthesis and release in gonadotroph monocultures under basal and GnRH-stimulated conditions. PRL receptor and dopamine receptor mRNA expressions were first determined by RT-PCR in both cell lines. Then, PRL and the dopamine agonist bromocriptine (Br), alone or in combination, were shown to block the maximal a-subunit and LHb-subunit mRNA responses to a dose-range of GnRH. The LH secretory response was differentially affected by treatments. GnRH dose-dependently stimulated LH release, with a 4-5 fold increase at 10 K8 M GnRH. Unexpectedly, PRL or Br stimulated basal LH release, with PRL, but not Br, enhancing the LH secretory response to GnRH. This effect was, however, completely blocked by Br. These results reveal direct effects of PRL and dopamine at the level of the gonadotroph cell, and interactions between these two hormones in the regulation of gonadotrophin secretion. Moreover, uncoupling between LH synthesis and release in both the basal and the GnRH-stimulated responses to PRL and dopamine was clearly apparent.
Introduction
Hyperprolactinaemia is a major cause of amenorrhoea in humans and has been shown to be associated with the suppression of gonadotrophin secretion and impaired fertility in this (Delvoye et al. 1978 , Kremer et al. 1991 , Blackwell 1992 and other (Bartke et al. 1977 , McNeilly et al. 1978 ) mammalian species. While the specific mechanisms underlying prolactin (PRL) effects on gonadotrophin release are still unresolved, it has become increasingly apparent that, in addition to the established actions of PRL at the level of the hypothalamus affecting gonadotrophin-releasing hormone (GnRH) output, interactions between the gonadotrophic and PRL axes occur at the level of the pituitary gland. Indeed, close associations between gonadotrophs and lactotrophs were originally identified in the rodent pituitary, where cell-to-cell communication in the form of adherans junctions (Horvath et al. 1977) and specific gap junction coupling (Morand et al. 1996) could be established. These morphological associations between the gonadotroph and lactotroph cells have also been identified in the pituitaries of larger vertebrates, where isolated gonadotrophs were shown to be situated within clusters of lactotrophs (Tortonese et al. 1998 , Gregory et al. 2000 .
Functional observations further support the existence of intrapituitary effects of PRL on gonadotrophin secretion. PRL receptor mRNA and protein have been detected within the pituitary gland of the rat (Chiu et al. 1992) , and treatment of cultured pituitary fragments with PRL resulted in the suppression of both basal and GnRH-stimulated luteinizing hormone (LH) release (Cheung 1983) . In humans, the pituitary LH response to GnRH is reduced during lactational amenorrhoea when PRL concentrations are elevated (Jeppsson et al. 1974 , Le Maire et al. 1974 , Andreassen & Tyson 1976 , and this has been associated with LH pulses of low amplitude (Tyson et al. 1978 , Glasier et al. 1984 . Similarly, in subhuman primates, exogenous PRL was shown to suppress the LH response to GnRH (Maneckjee et al. 1976 ). An additional evidence for a direct pituitary action of PRL on the gonadotrophic axis was revealed by a study reporting the selective expression of PRL receptors in gonadotroph cells of the pars distalis and pars tuberalis of the ovine pituitary, a species that shows overt temporal changes in fertility throughout the year in response to photoperiod (Tortonese et al. 1998 ). More recently, our laboratory demonstrated a seasonal modulation of the combined suppressive effects of PRL and dopamine on the gonadotrophin response to GnRH (Gregory et al. 2004 ).
An immortalised gonadotroph cell line, aT 3 -1, has been shown to express D 2 -type dopamine receptors and it has been suggested that these receptors negatively regulate pituitary a-subunit gene expression in association with a cAMP-dependent pathway (Kanasaki et al. 2002) , making it possible to investigate the direct effect of dopamine on a gonadotroph monoculture. aT 3 -1 is a mouse-derived cell line which expresses the mouse gonadotrophin a-subunit gene and synthesises and secretes the a-subunit protein (Windle et al. 1990 ). These cells also express GnRH receptors within the concentration range observed in primary gonadotrophs, and activation of these receptors evoked an equivalent response to GnRH by increasing the a-subunit mRNA in a dose-dependent manner (Windle et al. 1990 , Horn et al. 1991 . As the aT 3 -1 cell line was immortalised at a relatively early stage of development, it does not produce the gonadotrophin b-subunits. A similar cell line, LbT2, was created using tumorigenesis in transgenic mice carrying the LHb-subunit regulatory region (Alarid et al. 1996) . These cells express the gonadotrophin a-subunit, the LHb-subunit, GnRH receptor mRNA, and respond to GnRH with dosedependent increases in LH secretion, exhibiting functional characteristics consistent with those of normal pituitary gonadotrophs. Further studies have demonstrated LH secretion via a regulated pathway, and changes in GnRH receptor expression in response to signalling by GnRH and steroid hormones (Turgeon et al. 1996) . As the LbT2 cells represent aT 3 -1 cells arrested at a later stage of development, it seems probable that the LbT2 cell line will also express D 2 dopamine receptors. The expression of PRL receptors by either of these cell lines is yet to be determined. If present, the aT 3 -1 and/or LbT2 cell lines could offer a useful tool with which to investigate further the direct effects of PRL and dopamine on gonadotrophs.
The aim of this study was first to determine the expression of PRL receptors by aT 3 -1 and LbT2 cell lines, as well as the expression of dopamine receptors by LbT2 cells. Subsequently, these cell lines were used to investigate the combined suppressive effects of PRL and dopamine by measuring the gonadotrophin a-subunit and LHb-subunit mRNA responses to PRL and a dopamine agonist, alone or in combination, while simultaneously assessing the LH secretory response in the presence or absence of GnRH.
Materials and Methods
Cell culture and experimental design aT 3 -1 and LbT2 gonadotroph cells (a gift from Dr Pamela Mellon, University of California, San Diego, CA, USA) were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco) containing 10% fetal calf serum (PAA Laboratories, Linz, Austria) and 1% penicillin-streptomycin (Gibco), and maintained at 37 8C in an atmosphere of 95% air and 5% CO 2 . The cells were plated onto six-well plates at 3!10 5 cells/well for 4 days, and then either treated for 24 h or washed in PBS (calcium-, magnesium-and sodium bicarbonate-free, Gibco) and incubated in serum-free DMEM overnight before treatment was applied for 90 min. The cells were treated with: i) buffer (Control), ii) GnRH (10 K7 M), iii) bromocriptine (Br) (10 K8 M), iv) PRL (500 ng/ml), v) GnRHCBr, vi) GnRHC PRL and vii) GnRHCBrCPRL. The optimal GnRH dose required to generate a maximal mRNA response (i.e. 10 K7 M) was previously determined by dose-response tests at 90 min and 24 h. The doses of Br (a specific dopamine-D 2 receptor agonist) and PRL employed in this study were selected on the basis of their previously observed effectiveness at inducing a biological response in preliminary studies, and in previous work in aT 3 -1 (Kanasaki et al. 2002) and primary (Gregory et al. 2004) cultures. Following incubation, the medium was aspirated off prior to cell lysis and RNA extraction. GnRH and bromocriptine were purchased from Sigma-Aldridge Ltd, whereas PRL was obtained from Dr A F Parlow (ovine PRL, lot AFP-10692c, National Institute of Diabetes and Digestive and Kidney Diseases, NIDDKD, Torrance, CA, USA).
RT-PCR
Total RNA was extracted from aT 3 -1 and LbT2 cells, homogenised using QIAshredder columns (Qiagen) and purified using an RNeasy mini kit (Qiagen). mRNA was reverse-transcribed into single-stranded cDNA using oligo(dT)18 primer reverse transcriptase (Roche Diagnostics). cDNA samples were then subjected to PCR amplification using primers specific to: i) GAPDH, ii) a 645 bp product common to the short and long forms of the PRL receptor, iii) the long form of the D 2 dopamine receptor, iv) the gonadotrophin a-subunit and v) the LHb-subunit (for sequences see Table 1 ). PCR amplification was carried out using a MJ research PTC-200 Peltier Thermal Cycler.
The conditions consisted of an initial denaturation step at 95 8C for 2 min, followed by an amplification step at temperatures appropriate for each primer set (see Table 1 ) for 45 s, and extension at 72 8C for 1 min. The optimal number of amplification cycles for quantification of the products of each primer set had been previously determined by titration experiments. These were 23 cycles for the a-subunit and 25 cycles for the LHb-subunit expression. For the assessment of the expression of PRL and dopamine receptors, 35 cycles were used. Following amplification, the final 10 min extension step was carried out at 72 8C. PCR products were separated by electrophoresis on a 1 . 5% agarose gel containing 0 . 1 mg/ml ethidium bromide and quantified by scanning densitometry using Bio-Rad Quantity One Quantification Software. The amounts of PCR products of each subunit were normalised to those of the PCR products of GAPDH in each sample and the values were converted to a percentage of the control in order to allow a direct comparison between individual experiments (Kanasaki et al. 2002) .
RIA
The concentration of LH in culture medium following treatment was measured by RIA using reagents supplied by NIDDKD's National Hormone and Peptide Program and A F Parlow, with all samples being assayed in duplicate in the same assay. The reference preparation employed was mouse LH (AFP-5306A), with rat LH (AFP-11536B) for iodination, and rat LH antiserum (NIDDK-anti-rLH-S-11) as the primary antibody. The minimum detectable concentration was 0 . 1 ng/ml and the intra-assay coefficient of variation was 7 . 2%.
Statistical analysis
In both the aT 3 -1 and LbT2 cultures, six doses of GnRH were employed for dose-response tests, while for treatment effects, seven experimental groups were used. For each group, four wells were assigned to each treatment, and the experiments were carried out three times with reproducible results. The values are expressed as meansGS.E.M. The effects of treatments on the gonadotrophin subunit mRNA and secretory responses were examined by ANOVA, followed by pairwise comparison using Fisher's test to determine specific differences among treatments. Treatment effects were considered statistically significant at P!0 . 05.
Results

Expression of PRL and dopamine D 2 receptors in aT 3 -1 cells
In the first series of studies, total RNA from aT 3 -1 cells was analysed by RT-PCR to assess the presence of PRL receptors and confirm the expression of dopamine D 2 receptors. As shown in Fig. 1 , both the PRL receptor (645 bp) and the long form of the dopamine D 2 receptor (458 bp) mRNA were detected in aT 3 -1 cells.
Effects of PRL and dopamine on GnRH-induced a-subunit gene expression in aT 3 -1 cells Dose-response tests confirmed the ability of aT 3 -1 gonadotroph cells to respond to GnRH under culture conditions. Acute (90 min) treatment resulted in a clear dose-dependent response, with a 2 . 5-fold increase in a-subunit mRNA at 10 K7 M GnRH (P!0 . 01; Fig. 2A ). In contrast, chronic GnRH treatment (24 h) showed a moderate increase at all concentrations tested (P!0 . 05; Fig. 2B ). In the subsequent phase of this second series of studies, the acute application of PRL or Br did not modify basal a-subunit mRNA expression ( Fig. 3) . However, the a-subunit response to GnRH was totally suppressed when PRL or the dopamine agonist were applied alone or in combination (P!0 . 01). Similarly, in chronic (24 h) studies, a sub-maximal a-subunit response to GnRH was observed after treatment with PRL or Br (data not shown).
Expression of PRL and dopamine D 2 receptors in LbT2 cells
In the third series of studies, total RNA from LbT2 gonadotroph cells was analysed by RT-PCR to examine the expression of PRL and D2 dopamine receptors by this cell line. As shown in Fig. 1 , both PRL receptor (645 bp) and the long form of the dopamine D 2 receptor (458 bp) mRNA were detected in LbT2 cells.
Effects of PRL and dopamine on GnRH-induced LHb-subunit gene expression in LbT2 cells
In the fourth series of studies, LbT2 cultures were treated acutely (90 min) with increasing doses of GnRH (10 K9 -10 K6 M). A clear dose-response was observed, with maximal stimulation at 10 K7 M GnRH (P!0 . 01) (Fig. 4A ). In the second phase of this series of studies, treatment with PRL or Br, alone or in combination, completely suppressed the LHbsubunit mRNA response to GnRH (P!0 . 01) ( Fig. 5A ),
whereas the same treatments had no effect on basal mRNA expression. 
Effects of PRL and dopamine on LH secretion in LbT2 cells
In the final series of studies, LH concentrations in the media from LbT2 cultures were measured by RIA. GnRH stimulated LH release in a dose-dependent manner, with a fivefold increase at 10 K8 M GnRH (P!0 . 01) ( Fig. 4B ).
While treatments with PRL or Br alone stimulated LH release (P!0 . 01), PRL, and not Br, significantly enhanced the LH secretory response to GnRH (P!0 . 05). Interestingly, this effect was completely suppressed by the simultaneous addition of the dopamine agonist (P!0 . 01) (Fig. 5B ).
Discussion
The results of this study demonstrate the expression of functional PRL and dopamine receptors in gonadotroph cells. Indeed, suppression of the gonadotrophin mRNA response to GnRH at the level of both the aand b-subunits by PRL and a dopamine agonist (Br) was clearly apparent. Contrary to these observations, measurements of the LH secretory response in LbT2 gonadotrophs revealed that single applications of PRL or Br were capable of stimulating basal LH secretion under these culture conditions. Moreover, the LH response to GnRH was enhanced by PRL, while the co-application of Br with GnRH did not alter the LH secretory response in comparison with the stimulation by GnRH alone. Interestingly, when PRL was combined with the dopamine agonist, the PRL-induced increase in the LH secretory response to GnRH was completely abolished. While PRL is known to participate in the central control of fertility with well-documented effects in the hypothalamus, it is becoming increasingly apparent that PRL can also act directly at the level of the pituitary gland to regulate gonadotrophin output. Early morphological studies reporting intercellular interactions between gonadotroph and lactotroph cells in the rodent pituitary (Horvath et al. 1977 ) and the subsequent functional observations revealing hyperprolactinaemia-induced reduction of the LH secretory response to GnRH in rodents and humans (Cheung 1983) were subsequently supported by the identification of the two forms of the PRL receptor (gene and protein) within this tissue (Ouhit et al. 1993) , thus confirming that the infrastructure required for a direct pituitary action of PRL is indeed present. In the current study, the demonstration that both the PRL receptor and the DA receptor are expressed within the gonadotroph has important clinical implications, since it reveals that the gonadotroph itself can be a point for the control of fertility in hyperprolactinaemia-induced amenorrhoea. Indeed, the suppression of both gonadotrophin subunits mRNA responses to GnRH by PRL and bromocriptine shows that the secretory effects of this treatment originally detected in primary cultures are likely to be accompanied by changes in gene expression.
The inhibition of the mRNA response to GnRH by PRL and Br (alone or in combination) may involve a cross-talk between the intracellular signalling pathways activated by GnRH and those activated by PRL and/or dopamine. The common components in the signalling of one or more of these hormones are likely to be mediating these interactions. GnRH receptors are members of the G-protein-coupled receptor family; ligand binding leads to the activation of Gq and/or G11 proteins (Shah & Milligan 1994) , stimulation of phospholipase C (PLC), production of diacylglycerol (DAG) and activation of various protein kinase C (PKC) isoforms (Harris et al. 1997) . Downstream of this pathway, GnRH activates the extracellularly regulated kinase (ERK) cascade of the mitogen-activated protein kinase (MAPK) signalling pathway via a PKC and tyrosine kinase-dependent mechanism (Naor et al. 2000) . Simultaneously, GnRH induces intracellular calcium mobilisation and extracellular calcium influx (Stojilkovic et al. 1994) . PRL receptors are members of the cytokine family (Kelly et al. 1993) and are coupled to Janus Kinase 2, a tyrosine kinase. The activation of these receptors leads to phosphorylation, and thus activation of specific transcription factors from the signal transducer and activator of transcription (Stat) protein family (Ihle 1996) . The PRL receptor has also been implicated in the stimulation of MAPK cascades (Piccoletti et al. 1997) , and connections between the JAK-Stat and MAPK pathways have been suggested (Bole-Feysot et al. 1998) . Dopamine receptors, like GnRH receptors, are G-protein-coupled; these receptors are linked to G a 0 and/or G aI proteins (Enjalbert et al. 1988) . The activation of the dopamine receptor results in an immediate increase in intracellular potassium and a consequent reduction in the intracellular free calcium, leading to an inhibition of release from secretory granules (Gregerson 2001) . Additionally, dopamine acts to suppress PLC, thus reducing calcium release from the endoplasmic reticulum (Caccavelli et al. 1992) . The principal pathway responsible for reduced gene transcription following activation of the dopamine receptor results in the inhibition of adenylyl cyclase (Taussig & Gilman 1995) , decrease in cAMP production and suppression of activated PKA (Diamond et al. 1999) .
The dopamine and GnRH receptors therefore share many components involved in signal transduction. While GnRH activates PLC (Huckle & Conn 1987) , dopamine is known to have an inhibitory action, thus preventing the generation of inositol 1, 4, 5-triphosphate (IP3) and DAG (Vallar et al. 1988) and opposing the GnRH-induced increases in intracellular calcium concentration and PKC and MAPK activities (Levi et al. 1998) . Interestingly, MAPK activity has been suggested as a mediator of GnRH-induced stimulation of gonadotrophin subunit gene transcription (Roberson et al. 1995) . Consequently, by preventing the activation of PKC and inhibiting the increase in MAPK activity, dopamine may be able to decrease gonadotrophin subunit gene transcription. Conversely, the suggestion that PRL may also be involved in the activation of MAPK signalling cascades (Piccoletti et al. 1997) , leads to the possibility that overactivation of MAPK may underlie the observed inhibition of the gonadotrophin mRNA response to GnRH by PRL through a decrease in the cytoplasmic pool of ERK for subsequent phosphorylation. Therefore, the ERK/MAPK cascade may represent the common signalling pathway mediating the suppressive effects of dopamine and PRL on the gonadotrophin subunit mRNA response to the secretagogue.
The results of this study demonstrate an uncoupling between gonadotrophin synthesis and release in response to treatments, with the LH secretory response to GnRH not being inhibited by PRL or Br; in fact, PRL alone resulted in an enhancement of this response. Because the activation of calcium mobilisation associated with gonadotrophin release could run in parallel to, and to some extent be independent of, the activation of the ERK/MAPK pathway, the augmentation of the LH response to GnRH induced by PRL may result from the up-regulation of other signalling components. Indeed, we have recently observed that the stimulatory action of PRL on LH release is PKC-dependent (Hodson et al. 2008) . Given that GnRH activates PKC, and that the activation of this enzyme increases the affinity of intracellular calcium for hormone exocytosis (Zhu et al. 2002) , it is likely that PRL-induced activation of PKC accounts for the observed enhancement the LH secretory response to GnRH. Overall, the present findings are consistent with those of an early study in post-partum women where the LH response to exogenous GnRH was suppressed during the first month after parturition but enhanced above follicular phase levels in the second month (Keye & Jaffe 1976) . In the case of dopamine, the blockade of the PRL-induced enhancement of the secretory response to GnRH by the co-application of bromocriptine is an important observation, which corroborates previous findings in primary cultures (Gregory et al. 2004 ). If PRL is indeed inducing the observed enhancement through up-regulation of certain signalling components, dopamine is likely to be blocking these effects.
It thus becomes apparent that the paradoxical effects of PRL (i.e. whether stimulatory or inhibitory) on LH synthesis and release are likely to be dependent on the dopaminergic tone within the tissue. This may explain the apparent discrepancies in the reported associations between PRL and gonadotrophin secretion during lactational amenorrhoea in humans. Specifically, whereas some studies have provided evidence for a negative correlation between gonadotrophin secretion and PRL at this time ( Jeppsson et al. 1974 , Le Maire et al. 1974 , Andreassen & Tyson 1976 , Delvoye et al. 1978 , Duchen & McNeilly 1980 and that the duration of puerperal amenorrhoea is positively associated with the level of prolactinaemia (Diaz et al. 1989 (Diaz et al. , 1991 , others have found no correlation between the two (Nunley et al. 1991 , Tay et al. 1992 . In a study where dopamine and opioid antagonists were administered to breastfeeding women, the resulting increases in endogenous PRL secretion did not significantly affect the gonadotrophin responses to an injection of GnRH (Tay et al. 1993) . Since in the present study the LH secretory response to the secretagogue was enhanced by PRL, and that effect was unambiguously blocked by DA, it would be thus pertinent to consider what mechanisms could develop in vivo in some circumstances to counteract the suppressive effects of hyperprolactinaemia on the reproductive axis reported by others and/or the robust treatment effects observed here in vitro.
In conclusion, this study has demonstrated the expression of functional PRL and dopamine receptors by gonadotroph cells. These receptors were shown to mediate the suppressive effects of PRL and a dopamine agonist on the gonadotrophin mRNA response to GnRH, not only at the level of the common a-subunit but also affecting the LHb-subunit. In contrast, the LH secretory response to GnRH was augmented by PRL. While the dopamine agonist did not share this ability, it was able to block the enhancing effect of PRL when the two were co-applied. These results have important clinical implications since they provide evidence for uncoupling between gonadotrophin synthesis and release in response to treatments; they also support previous observations in primary cultures revealing that the combined suppressive effects of PRL and dopamine on the gonadotrophin response to GnRH are accompanied by alterations in gonadotrophin subunit mRNA expression. 
